|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Biological function results illustrated that knockdown of GALNT6 inhibited proliferation, migration and invasion of MDA-MB-231 cells, and increased cell apoptosis.
|
30662357 |
2019 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
AKT rescue experiment found that AKT was involved in GALNT6-induced CRC cell migration and invasion.
|
30662801 |
2018 |
|
Tumor Cell Invasion
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
Both GalNAc-T3 and GalNAc-T6 expression levels were downregulated in ectopic endometrium, which may increase the adhesion and invasion of endometrial cells and contribute to the development of EMS.
|
28382414 |
2017 |
|
Tumor Cell Invasion
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
The results suggested that positive GalNAc-T6 expression is significantly associated with histological grade of tumors and myometrial invasion characteristic.
|
28560066 |
2017 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
GalNAc-T6 might be related to cell-cell adhesion in the early phase of cancer invasion in endometrial carcinoma.
|
28668893 |
2017 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
GALNT6 knockdown with two independent siRNAs significantly suppressed viability, migration, and invasion of ovarian cancer cells.
|
28388560 |
2017 |
|
Malignant neoplasm of breast
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of GALNT6 in breast cancer cell attenuated the protein expression of PCNA, cyclin D1, C-myc and β-catenin, and increased the expression of E-cadherin, caspase 3 and cleaved PARP1.
|
30662357 |
2019 |
|
Breast Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of GALNT6 in breast cancer cell attenuated the protein expression of PCNA, cyclin D1, C-myc and β-catenin, and increased the expression of E-cadherin, caspase 3 and cleaved PARP1.
|
30662357 |
2019 |
|
Malignant neoplasm of breast
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of GALNT6 expression in two breast cancer cell lines, T47D and MCF7, in which both ER-α and GALNT6 were highly expressed, by small interfering RNA could significantly attenuate expression of ER-α.
|
30208353 |
2018 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
<i>GALNT6</i> silencing in SW480 cells promoted invasion, migration, chemoresistance, and increased cell surface expression of a cancer-associated truncated O-glycan, Tn-antigen.<b>Conclusions:</b> The 15-glycogene signature and the expression levels of GALNT6 mRNA and protein each serve as a novel prognostic biomarker, highlighting the role of dysregulated glycogenes in cancer-associated glycan synthesis and poor prognosis.<i>Clin Cancer Res; 24(18); 4468-81.©2018 AACR</i>.
|
29844132 |
2018 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
These results were verified by immunohistochemistry, suggesting that GalNAc-T6 plays a role in colon carcinogenesis.
|
29187600 |
2018 |
|
Breast Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of GALNT6 expression in two breast cancer cell lines, T47D and MCF7, in which both ER-α and GALNT6 were highly expressed, by small interfering RNA could significantly attenuate expression of ER-α.
|
30208353 |
2018 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
<i>GALNT6</i> silencing in SW480 cells promoted invasion, migration, chemoresistance, and increased cell surface expression of a cancer-associated truncated O-glycan, Tn-antigen.<b>Conclusions:</b> The 15-glycogene signature and the expression levels of GALNT6 mRNA and protein each serve as a novel prognostic biomarker, highlighting the role of dysregulated glycogenes in cancer-associated glycan synthesis and poor prognosis.<i>Clin Cancer Res; 24(18); 4468-81.©2018 AACR</i>.
|
29844132 |
2018 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
These are often involved in cell-cell adhesion, cytoskeleton regulation and immune recognition. pp-GalNAc-T6 has been shown to be upregulated in a number of types of cancer.
|
27659430 |
2017 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
GalNAc-T6 might be related to cell-cell adhesion in the early phase of cancer invasion in endometrial carcinoma.
|
28668893 |
2017 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Collectively, our study revealed biological significances of O-glycosylation of GRP78 protein, which might play significant roles in the survival of cancer cells, and thus provided a new insight in cancer cell death and useful information for development of anti-cancer treatment targeting the GALNT6-GRP78 pathway.
|
28110670 |
2017 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
We previously reported that overexpression of an O-type glycosyltransferase, GALNT6 (polypeptide N-acetylgalactosaminyltransferase 6) played critical roles in mammary carcinogenesis.
|
28110670 |
2017 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
N-acetylgalactosaminyltransferase 6 (GALNT6), an enzyme that mediates the initial step of mucin type-O glycosylation, has been reported to regulate mammary carcinogenesis.
|
28388560 |
2017 |
|
Carcinogenesis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Positive expression of N-acetylgalactosaminyltransferase-6 (GalNAc-T6) may also be a marker for aberrant O-glycans in carcinogenesis.
|
28668893 |
2017 |
|
Primary malignant neoplasm
|
0.050 |
AlteredExpression
|
group |
BEFREE |
These are often involved in cell-cell adhesion, cytoskeleton regulation and immune recognition. pp-GalNAc-T6 has been shown to be upregulated in a number of types of cancer.
|
27659430 |
2017 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
Collectively, our study revealed biological significances of O-glycosylation of GRP78 protein, which might play significant roles in the survival of cancer cells, and thus provided a new insight in cancer cell death and useful information for development of anti-cancer treatment targeting the GALNT6-GRP78 pathway.
|
28110670 |
2017 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
GalNAc-T6 might be related to cell-cell adhesion in the early phase of cancer invasion in endometrial carcinoma.
|
28668893 |
2017 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
We previously suggested that polypeptide N-acetylgalactosaminyltransferase 6 (GALNT6), which catalyzes O-type glycosylation of Mucin 1, might be a promising molecular target for drug development for breast cancer.
|
27237318 |
2016 |